Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

Clin Cancer Res. 2011 Aug 1;17(15):4919-21. doi: 10.1158/1078-0432.CCR-11-1218. Epub 2011 Jun 13.

Abstract

Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzoquinones / administration & dosage*
  • Breast Neoplasms / drug therapy*
  • Female
  • Genes, erbB-2*
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Lactams, Macrocyclic / administration & dosage*
  • Male
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Benzoquinones
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • tanespimycin
  • Trastuzumab